Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence. The company also distributes private labeled products, such as electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support. In addition, it develops non-invasive blood volume monitors for use in hospitals and surgery centers. The company offers its products for pain management and control; and stroke and spinal cord injury rehabilitation. It sells its products through direct and independent sales representatives primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ZYXI
Previous Symbol
CUSIPN/A
Phone303-703-4906
Debt
Debt-to-Equity RatioN/A
Current Ratio3.45
Quick Ratio2.98
Price-To-Earnings
Trailing P/E Ratio14.32
Forward P/E Ratio11.25
P/E GrowthN/A
Sales & Book Value
Annual Sales$23.43 million
Price / Sales4.47
Cash Flow$0.2370 per share
Price / Cash13.29
Book Value$0.27 per share
Price / Book11.67
Profitability
EPS (Most Recent Fiscal Year)$0.22
Net Income$7.36 million
Net Margins33.33%
Return on Equity152.81%
Return on Assets95.46%
Miscellaneous
Employees109
Outstanding Shares33,280,000
Market Cap$109.83 million
OptionableNot Optionable
Zynex (OTCMKTS:ZYXI) Frequently Asked Questions
What is Zynex's stock symbol?
Zynex trades on the OTCMKTS under the ticker symbol "ZYXI."
How were Zynex's earnings last quarter?
Zynex Inc. (OTCMKTS:ZYXI) announced its earnings results on Tuesday, November, 6th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.07 by $0.01. The company had revenue of $8.13 million for the quarter, compared to analysts' expectations of $7.96 million. Zynex had a net margin of 33.33% and a return on equity of 152.81%. View Zynex's Earnings History.
What price target have analysts set for ZYXI?
1 equities research analysts have issued 12-month price objectives for Zynex's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate Zynex's stock price to reach $7.00 in the next year. This suggests a possible upside of 122.2% from the stock's current price. View Analyst Price Targets for Zynex.
What is the consensus analysts' recommendation for Zynex?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zynex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zynex.
Has Zynex been receiving favorable news coverage?
Media coverage about ZYXI stock has been trending somewhat positive this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zynex earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Zynex's key competitors?
Some companies that are related to Zynex include Cutera (CUTR), Electrocore (ECOR), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Semler Scientific (SMLR), Fonar (FONR), Second Sight Medical Products (EYES), Viveve Medical (VIVE), Stereotaxis (STXS), Edap Tms (EDAP), IRIDEX (IRIX), Soleno Therapeutics (SLNO), ENDRA Life Sciences (NDRA), Digirad (DRAD) and Precision Optics (PEYE).
Who are Zynex's key executives?
Zynex's management team includes the folowing people:
- Mr. Thomas Sandgaard, Founder, Pres, CEO & Chairman (Age 59)
- Mr. Daniel J. Moorhead, Chief Financial Officer (Age 46)
- Mr. David B. Mogill, VP of Operations
- Mr. Robert Bird, VP of Marketing
- Mr. Steve Siefring, Director of Bus. Devel.
How do I buy shares of Zynex?
Shares of ZYXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zynex's stock price today?
One share of ZYXI stock can currently be purchased for approximately $3.15.
How big of a company is Zynex?
Zynex has a market capitalization of $109.83 million and generates $23.43 million in revenue each year. The company earns $7.36 million in net income (profit) each year or $0.22 on an earnings per share basis. Zynex employs 109 workers across the globe.
What is Zynex's official website?
How can I contact Zynex?
Zynex's mailing address is 9555 MAROON CIRCLE, ENGLEWOOD CO, 80112. The company can be reached via phone at 303-703-4906 or via email at [email protected]
MarketBeat Community Rating for Zynex (OTCMKTS ZYXI)
MarketBeat's community ratings are surveys of what our community members think about Zynex and other stocks. Vote "Outperform" if you believe ZYXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
